The EndoSound Vision System reportedly enables providers to convert existing upper gastrointestinal endoscopes into endoscopic ultrasound modalities.
The Food and Drug Administration (FDA) has cleared the EndoSound Vision System (EndoSound), a modality that may help broaden access to endoscopic ultrasound for gastrointestinal diseases.
EndoSound said the EndoSound Vision System (EVS) can be attached to existing upper gastrointestinal endoscopes. While the company noted that 95 percent of endoscopic ultrasound services are performed in hospital settings, it maintained that the “more economical” EVS may allow more use of the technology in ambulatory care settings.
The EndoSound Vision System, which previously garnered an FDA Breakthrough Device Designation in July 2021, provides detailed gastrointestinal imaging, and also addresses the issue of infections that may occur with endoscope elevators that are difficult to clean, according to EndoSound.
“This (FDA clearance) milestone underscores our commitment to advancing medical technology and improving patient outcomes. With the EVS, we aim to not only enhance the safety of endoscopic procedures but also contribute to expanding access to care for patients worldwide,” noted Stephen Steinberg, M.D., the president and CEO of EndoSound.
(Editor’s note: For related content, see “Endoscopic Ultrasound Biopsy Modality Gets FDA Nod” and “AI-Powered Liver Tumor Ablation Software Leverages CT, MRI and Ultrasound for Real-Time Image Guidance” and “Diagnostic Imaging’s Top Five Ultrasound Content of 2023.”)
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Week, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.